New Haven, Connecticut 06510

  • Alanine Aminotransferase, Plasma Level of, Quantitative Trait Locus 1

Purpose:

To explore whether there is a different response to omega-3 fatty acid rich diet with respect to the hepatic fat fraction % (HFF), triglyceride, and ALT levels between the rs738409 minor allele (GG) and the common allele homozygous (CC) of PNPLA3. Hypothesis: We expect that subjects homozygous for the minor allele of the rs73049 SNP will lower their triglyceride, hepatic fat content, and ALT levels more with dietary intervention than the common allele homozygous supplementation.


Study summary:

Nonalcoholic fatty liver disease (NAFLD) is emerging as one of the most common complications of childhood obesity. It is associated with and predicts the metabolic syndrome, independent of overall obesity. Increased ALT levels are associated with deterioration in insulin sensitivity and glucose tolerance, as well as with increasing free fatty acid (FFA) and triglyceride levels. The prevalence of metabolic syndrome and prediabetes increases with the increases in hepatic fat content in a cohort of obese adolescents. Fatty liver, independent of visceral and intramyocellular lipid content plays a central role in the impairment of liver, muscle and adipose insulin sensitivity in obese adolescents. Thus, fatty liver disease may be the hepatic component of the metabolic syndrome. Omega 3 fatty acids lower plasma triglyceride concentrations. The subjects entering the omega diet study will be consuming an omega rich diet that is tailored to their caloric needs. This calculation is based on the patient's weight, age, and gender with the purpose of not modifying their weight at all. Weight maintenance is a very important factor in this arm of the study. They will be on the diet for 12 weeks.


Criteria:

Inclusion Criteria: - 10 to 19 years of age - BMI equal or greater than the 95th percentile for age and gender - Genotype PNPLA3 CC or GG - Liver MRI Hepatic Fat fraction ≥5.5% Exclusion Criteria: - Food allergy to fish or any components of the pills which include alpha tocopherol partially hydrogenated vegetable oils including soybean oils, gelatin, glycerol, corn or iron oxide - Pregnant or breastfeeding - Known bleeding disorder or coagulopathy or treatment with anticoagulant mechanisms or low platelet counts, abnormal PT or PTT - Impaired glucose tolerance, Type 1 or 2 diabetes - Birth control pills - Alcohol consumption - Other liver disease - Taking any medication that alters triglyceride levels, liver function, blood pressure, glucose or lipid metabolism - Taking over the counter supplements that affect triglycerides or lipid metabolism including fish oil supplements - Treatment for or diagnosis of thyroid disorder or have an elevated TSH at baseline - Use of any antipsychotic medication - Taking chronic anti-inflammatory medications - Less than 100 pounds (45 kg)


NCT ID:

NCT01556113


Primary Contact:

Principal Investigator
Nicola Santoro, MD/PhD
Yale University

Bridget Pierpont, M.A.
Phone: 203-785-2942
Email: bridget.pierpont@yale.edu


Backup Contact:

N/A


Location Contact:

New Haven, Connecticut 06510
United States

Bridget Pierpont, M.A.
Phone: 203-785-2942
Email: bridget.pierpont@yale.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: September 27, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.